This tropical disease is second only to malaria as a parasitic killer. So why haven't you heard of it?

June 7, 2018 by Bill Ibelle, Northeastern University
Credit: Northeastern University

One form of the disease begins with large open sores that won't heal, then migrates to the nose and lips, rotting them away like a form of leprosy and leaving the victim badly disfigured.

Another strain isn't nearly as visibly grotesque, but it's far more deadly, attacking the spleen, liver, and bone marrow.

The of the disease, , infects 300,000 people annually, causing 20,000 deaths, according to the World Health Organization. It is the second largest cause of parasitic death after malaria. Another 1 million people are infected with annually and more than 500 million worldwide are at risk for contracting some form of the disease.

You may wonder why you've never heard of such a horrid, deadly, and widespread disease.

The answer is simple—it's a suffered primarily by the most impoverished populations in the world. While it poses a risk to American soldiers, researchers, and adventure travelers, the vast majority of cases are found among rural populations in equatorial countries. So for most of the developed world, leishmaniasis is a distant threat.

But for two Northeastern professors, Richard Wamai and Michael Pollastri, controlling the disease is a top priority. The two co-founded the Integrated Initiative for Global Health at Northeastern to spearhead their interdisciplinary work on neglected diseases.

Wamai, an expert in , is building a research center in rural Kenya, where he has been conducting research on leishmaniasis for the past eight years. Kenya is one of the seven countries that account for 90 percent of the reported cases of the disease. To advance experiential learning at Northeastern, he has invited students to participate in many of his research trips to the African nation.

Pollastri is attacking the problem in his Northeastern lab, where he develops new medicines to combat neglected tropical diseases. Although the two men are approaching the disease from different disciplines, one as a social scientist and the other as a chemist, they are working collaboratively toward the same goal.

In 2011, Wamai and Pollastri received a $50,000 seed grant from Northeastern to conduct preliminary field research in Kenya needed to win major grants from the National Institutes of Health and other private sources.

"That experience is why my lab got so deeply into this," said Pollastri. "People were walking 20 kilometers with their whole family to get tested. The kids who suffered from this were the same age as my kids, who were 9 and 4 at the time. This isn't just some academic exercise. It's as real as it gets."

A personal mission

Wamai grew up in a rural Kenyan village with no electricity, running water, or indoor toilets. He didn't have his first pair of shoes until he was 13, and like the other kids in his village, he ran barefoot to school each day. When the kids cut themselves working in the fields, they bound their wounds with dirt to stop the bleeding, which often caused more serious problems.

"Growing up, every little boy had intestinal worms at some point," he said.

"Mothers would know because their children would be eating and not gaining weight."

In 1983, at age 13, Wamai took the national test that Kenya administers to determine which children will continue their education.

"I was the top candidate in my district, so I went to a national boarding school 10 miles from my house," he said. "That's when I got my first pair of shoes and trousers."

He did so well in school that he was transferred to an advanced academy 300 miles from his home near the Somali border. That eventually led to a degree in sociology at the Egerton University in Kenya and a doctorate in international health at the University of Helsinki in Finland.

Explore further: Team advances in developing vaccine for cutaneous leishmaniasis

Related Stories

Team advances in developing vaccine for cutaneous leishmaniasis

November 15, 2017
A research team at The University of Texas at El Paso is one step closer to developing an effective human vaccine for cutaneous leishmaniasis, a tropical disease found in Texas and Oklahoma, and affecting some U.S. troops ...

New hope for drug discovery in African sleeping sickness

October 24, 2014
In early drug discovery, you need a starting point, says Northeastern University associate professor of chemistry and chemical biology Michael Pollastri.

Crowdfunding drug discovery

October 29, 2013
During his nine years working in the pharmaceutical industry, Michael Pollastri learned to protect his research and data with extreme caution. "In the drug industry, everything is super secret," said Pollastri, now an associate ...

A novel oral treatment for leishmaniasis has potential to save thousands of lives

October 24, 2011
A tropically stable liquid therapy for leishmaniasis, a disease known as the Baghdad boil, shows a significant decrease in infection after less than a week of treatment. This research is being presented at the 2011 American ...

Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa

April 13, 2018
A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA Consortium ...

Recommended for you

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.

Cell-free DNA profiling informative way to monitor urinary tract infections

June 20, 2018
Using shotgun DNA sequencing, Cornell University researchers have demonstrated a new method for monitoring urinary tract infections (UTIs) that surpasses traditional methods in providing valuable information about the dynamics ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

rgoff
not rated yet Jun 07, 2018
Dear Northeastern University,
You being by implying that I have never heard of this disease. Then, in the lead paragraph, you fail to name it. This forces me to click on the article. I hate clickbait. I've heard of the disease. Get an editor.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.